Dossier assessment
Tislelizumab (oesophageal squamous cell carcinoma, first line) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Tislelizumab (Ösophaguskarzinom, fortgeschritten, Erstlinie) Nutzenbewertung gemäß § 35a SGB V
-
Dossier assessment
Tislelizumab (Ösophaguskarzinom, fortgeschritten, Erstlinie) Nutzenbewertung gemäß § 35a SGB V
Dossier assessment
Adults with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma that is not treatable with curative intent, whose tumours express PD-L1 with a Tumour Area Positivity score ≥ 5%
- Patients with tumour cell PD-L1 expression ≥ 1% or a combined positive score (CPS) ≥ 10; first-line treatment: added benefit not proven
- Patients with no tumour cell PD-L1 expression ≥ 1% and no CPS ≥ 10; first-line treatment: added benefit not proven
Project details
- Project no.
- A24-129
- Commission
- Commission awarded on 20.12.2024 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
The current version 1.1 of the Dossier assessment replaces version 1.0 published on 01.04.2025.
- DOI
https://doi.org/10.60584/A24-129_V1.1_en
Connected Projects
-
Dossier assessment
Tislelizumab (gastric or gastroesophageal junction adenocarcinoma, HER2-negative) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Tislelizumab (oesophageal carcinoma, advanced, second line) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Tislelizumab (non-squamous NSCLC) - Benefit assessment according to §35a Social Code Book (SGB) V
Status: Commission completed
-
Dossier assessment
Tislelizumab (squamous NSCLC, first line) – Benefit assessment according to §35a Social Code Book (SGB) V
Status: Commission completed
-
Dossier assessment
Tislelizumab (NSCLC, second line) - Benefit assessment according to § 35a Social Code Book (SGB) V
Status: Commission completed
-
Dossier assessment
Tislelizumab (NSCLC, neoadjuvant + adjuvant) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Tislelizumab (nasopharyngeal carcinoma) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Tislelizumab (small cell lung cancer, extensive stage) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed